a S c i T e c h n o l j o u r n a lEditorial

Mahendru and Bansal, J Genit Syst Disor 2015, 4:3http://dx.doi.org/10.4172/2325-9728.1000e108 Journal of Genital

System & Disorders

All articles published in Journal of Genital System & Disorders are the property of SciTechnol, and is protected by copyright laws. Copyright © 2015, SciTechnol, All Rights Reserved.International Publisher of Science,

Technology and Medicine

Leiomyoma through History: An Overview Rajiv Mahendru1* and Saloni Bansal2

*Corresponding author: Rajiv Mahendru, Professor and Head, Dept of Obstetrics and Gynaecology, BPS, Government Medical College for Women, Khanpur Kalan (Sonepat), Haryana, India, Tel: +91 94160 86483; E-mail: dr.rmahendru@gmail.com

Received: June 12, 2015 Accepted: June 16, 2015 Published: June 22, 2015

in only 3% of cases. Fibroids that give a call for infertility are the ones with diameter more than 50mm, located near cervix or tubal ostium or submucosal ones. Further, a cause of alarm is pregnancy related complications. Reviews suggest an increased risk of spontaneous abortions, premature delivery, malpresentation, stillbirth, abruption placenta and post-partum haemorrhage. Moreover, there are a few uncommon symptoms and presentations allocated to them like ascites, pseudo-Meig’s syndrome, Polycythemia and deep vein thrombosis. Some women may complain of pelvic discomfort, heaviness, Dyspareunia and/ or non-cyclic pelvic pain or simply abdominal distention [3,7]. Association of onset of pain and/or bleeding in postmenopausal women calls for considering sarcomata’s changes in a previously silent leiomyoma [8].

ComplicationsApart from hyaline, hydropic, myxoid and fatty degeneration,

red degeneration (specific to pregnant uterus), cases may land up with calcification, infection, suppuration, necrosis and sarcomatous degeration (0.7%). Other complications that can sometimes accompany an otherwise innocent myoma are intrabdominal bleeding, uterine torsion, hydroureter/hydronephrosis, urinary retention, renal failure, venous thromboembolism or mesenteric vein thrombosis [3].

BackgroundLeiomyomas or Uterine fibroids are benign tumors that originate

from the smooth muscle of the uterus and represent the most common tumor of the female reproductive tract with estimated incidence of around 50% [1]. They affect women of reproductive age and tend to regress following menopause [2].

PathophysiologyMyomas can be single or multiple and can vary in size, location,

and perfusion; commonly classified into 3 subgroups based on their location: subserosal (projecting outside the uterus), intramural (within the confines of the uterine musculature) and submucosal (encroaching upon the uterine cavity). They are well circumscribed tumors but without a capsule, rather they have a pseudocapsule, which is a neurofibrovascular structure containing many neuropeptides and neurotransmitters, which are important for reproductive and sexual functions [3].

Location wise they are much less often in the cervix than the uterine corpus, may develop in round ligament, albeit rare. Further, they can be parasitic/wandering fibroids (Figure 1), epitheloid, intraligamentary (broad ligament). In some cases large intraligamentary fibroids are located outside pelvis and form a type of retroperitoneal tumor [4] (Figure 2).

Risk FactorsBeing an oestogen dependent tumour, it is common in older

nulliparous women with early menarche and the risk decreases with each pregnancy. Specific clinical conditions, such as hypertension or diabetes and obesity put a greater risk. Smoking categorically is protective to such tumors [5].

Clinical PictureAlthough, majority being asymptomatic, less than 50%, may

present with abnormal bleeding depending upon their size, site and number [6]. Other usual presentations may be due to pressure symptoms resulting into urgency, frequency or sometimes even urinary incontinence. On the contrary, it may be urinary retention with overflow incontinence due to urethral or bladder neck compression.

Fibroids are not so common a cause of infertility and are a culprit

Figure 1: Intra-operative image of wandering/parasitic leiomyoma.

Figure 2: Intra-operative image of retroperitoneal leiomyoma.

Citation: Mahendru R, Bansal S (2015) Leiomyoma through History: An Overview. J Genit Syst Disor 4:3.

• Page 2 of 3 •

doi:http://dx.doi.org/10.4172/2325-9728.1000e108

Volume 4 • Issue 3 • 1000e108

EvaluationImaging techniques [9], including Transvaginal and abdominal

ultrasonography, sonohysterography, hysterosalpingography, hysteroscopy, and magnetic resonance imaging (MRI) [10], are helpful to confirm the clinical suspicion.

ManagementVarious treatment modalities ranging from medical, minimally

invasive to conservative surgeries and hysterectomy are available. A basket of modalities can be made available to the patient and choice can be made depending upon individual’s need and requirements for preservation of fertility and or the uterus. According to certain studies, indication is that 3% to 7% of small asymptomatic untreated fibroids regress over 6 months to 3 years in pre- and peri-menopausal women [11].

Medical ManagementAnti inflammatory, oral Contraceptives and progestins

[12] form the basis for symptomatic relief from good olden times. Further therapies like levonorgestrel Intrauterine System (LNG-IUS) [12], Gonadotropin-Releasing Hormone Agonists, Gonadotropin-Releasing Hormone Antagonists [13], Aromatase Inhibitors(Letrozole), Estrogen Receptor Antagonists [14], Selective Estrogen Receptor Modulators SERMs), Selective Progesterone Receptor Modulators (SPRMs) and Mifepristone [15].

Ulipristal acetate

Has been shown to exhibit antiproliferative effects on myometrial cells and the Endometrium [16].

Surgical TherapiesThe ideal surgical treatment should satisfy three goals: relief

of signs and symptoms, sustained reduction of fibroid size, and maintenance or improvement of fertility.

Pre-surgical Medical ApproachesMedical treatments are often used to control bleeding, shrink

fibroid bulk, reduce uterine size, and increase the hemoglobin level prior to surgery.

Conventional Surgical ApproachesHysterectomy

Hysterectomy remains the most common surgical treatment whether it is performed by abdominal, laparoscopic, or vaginal route, should be based on surgeon’s training, experience, and comfort and on clinical practice guidelines [17]. According to surveys, in the United States, leiomyomas account for approximately one third of hysterectomies performed annually [18].

Myomectomy

Myomectomy is an alternative to hysterectomy for women who wish to retain their uterus, regardless of their fertility desire. Removal of fibroids should be considered if they are thought to be associated with heavy menstrual bleeding, pelvic pain and/or pressure symptoms, and in some cases reproductive issues [19]. Women should be counseled about the risks of requiring a hysterectomy at the time of a planned myomectomy. This would depend on the intraoperative findings and the course of the surgery.

Can be intraabdominal, intracapsular myomectomy [20], hysteroscopic myomectomy [12], laparoscopic myomectomy [21] limited by number and size of fibroid and, at times, caesarean myomectomy [22].

Other Approaches can be Robotic assisted laparoscopy [12] and mini-laparotomy hysterectomy [23].

Intraoperative AdjunctsLike vasopressin, bupivacaine and epinephrine, misoprostol,

peri-cervical tourniquet, or gelatin-thrombin matrix have been used for reduction of blood loss during myomectomy procedures. Other Conservative Treatments like uterine artery embolization (UAE) and endometrial ablation [24] are also reliable options.

Focused Energy Delivery Systems, MR-guided focused ultrasound and Radiofrequency myolysis are the newer developments.

To Summarize Uterine fibroids are one of the common gynaecological concerns

in fertile age group women, especially over 40s

Although many women with leiomyomas may be free of symptoms, whereby, necessitating no immediate intervention, those who become symptomatic can experience significant morbidity and a deterioration of their quality of life.

Uterine fibroids mostly cause abnormal bleeding problems and other symptoms might impact poorly on women’s life, influencing their sexual, social and work life.

Invasive surgical treatments have long been the mainstay of the management of Leiomyoma like myomectomy (conservative) or hysterectomy (definitive).

Uterine artery embolization is one of the currently available and futuristic conservative interventional treatments which have depicted effectiveness.

Of late, focused energy delivery methods have shown encouraging results.

Recent evidence regarding ulipristal actetate suggests the agent may hold potential capability in the long-term management of leiomyomas.

Acknowledgement

In preparing this manuscript, the author sincerely acknowledges the assistance and contribution of his assistant professors Dr. Saloni Bansal and Dr. Vijayata.

References

1. Evans P, Brunsell S (2007) Uterine Fibroid Tumors: Diagnosis and Treatment. Am Fam Physician 75: 1503-1508.

2. Fields KR, Neinstein LS (1996) Uterine myomas in adolescents: case reports and a review of the literature. J Pediatr Adolesc Gynecol 9: 195-198.

3. Sparic R, Terzic M, Malvasi A, Tinelli A (2015) Uterine fibroids- clinical presentation and complications. ACI LXI: 41-48.

4. Mahendru R, Geetinder G, Yadav S, Gurmeet G, Gupta C (2012) A Rare Case of Retroperitoneal Leiomyoma. Case Reports in Surgery 2012: 01-03.

5. Ryan GL, Syrop CH, Van Voorhis BJ (2005) Role, epidemiology, and natural history of benign uterine mass lesions. Clin Obstet Gynecol 48: 312-324.

6. Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Steege JF, et al. (2003) Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 101: 431-437.

Citation: Mahendru R, Bansal S (2015) Leiomyoma through History: An Overview. J Genit Syst Disor 4:3.

• Page 3 of 3 •

doi:http://dx.doi.org/10.4172/2325-9728.1000e108

Volume 4 • Issue 3 • 1000e108

7. Lippman SA, Warner M, Samuels S, Olive D, Vercellini P, et al. (2003) Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 80: 1488-1494.

8. Schwartz LB, Diamond MP, Schwartz PE (1993) Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 168: 180-183.

9. Cantuaria GH, Anglioli R, Frost L, Duncan R, Penalver MA (1998) Comparison of bimanual examination with ultrasound before hysterectomy for uterine leiomyoma. Obstet Gynecol 92: 109-112.

10. Stamatopoulos CP, MikosT, Grimbizis GF, Dimitriadis AS, Efstratiou I, et al. (2012) Value of magnetic resonance imaging in diagnosis of adenomyosis and myomas of the uterus. J Minim Invasive Gynecol 19: 620-626.

11. Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, et al. (2008) Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA. 105: 19887-19892.

12. Vilos GA, Allaire C, Laberge PY, Leyland N, Vilos AG, et al. (2015) The Management of Uterine Leiomyomas J Obstet Gynaecol Can 37: 157-181.

13. Britten JL, Malik M, Levy G, Mendoza M, Catherino WH (2012) Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production. Fertil Steril 98: 1299-1307.

14. Donnez J, Hervais VB, Kudela M, Audebert A, Jadoul P (2003) A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil Steril 79:1380-1389.

15. Shen Q, Hua Y, Jiang W, Zhang W, Chen M, et al. (2013) Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 100: 1722-1726.

16. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group (2007) Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92: 3582-3589.

17. Lefebvre G, Allaire C, Jeffrey J, Vilos G (2002) Hysterectomy: SOGC Clinical Practice Guidelines. J Obstet Gynaecol Can 24: 01-11.

18. Merrill RM (2008) Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 14: CR24-CR31.

19. Carranza-Mamane B, Havelock J, Hemmings R (2015) The Management of Uterine Fibroids in Women with Otherwise Unexplained Infertility: SOGC Clinical Practice Guidelines. J Obstet Gynaecol Can 37: 277-285.

20. Sparić R, Nejković L, Mutavdžić D, Malvasi A, Tinelli A (2013) Conservative surgical treatment of uterine fibroids. ACI LXI: 11-16.

21. Malzoni M, Tinelli R, Cosentino F, Iuzzolino D, Surico D, et al. (2010) Laparoscopy versus minilaparotomy in women with symptomatic uterine myomas: short-term and fertility results. Fertil Steril 93: 2368–2373.

22. Mahendru R, Sekhon PK, Gaba G, Yadav S (2011) At times, myomectomy is mandatory to effect delivery. Ann Surg Innov Res 5: 9.

23. Mahendru R, Malik S, Mittal A, Sekhon PK, Malik N, et al. (2011) Minilaparotomy hysterectomy: a worthwhile alternative. J Obstet Gynaecol Res 37: 305-312.

24. National Collaborating Centre for Women’s and Children’s Health (2007) Heavy menstrual bleeding. Clinical Guideline.

Submit your next manuscript and get advantages of SciTechnol submissions

� 50 Journals � 21 Day rapid review process � 1000 Editorial team � 2 Million readers � Publication immediately after acceptance � Quality and quick editorial, review processing

Submit your next manuscript at ● www.scitechnol.com/submission

Author Affiliation Top1Dept of Obstetrics and Gynaecology, BPS Government Medical College for Women, Khanpur, Kalan (Sonepat), Haryana, India2Deptt of Obstetrics and Gynaecology, BPS Government Medical College for Women, Khanpur, Kalan (Sonepat), Haryana, India